A randomized double-blind placebo-controlled dose ranging phase 2 study of ISIS 681257 administered subcutaneously to patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD)

A phase 2 randomized, double-blind, placebo-controlled, dose-ranging study in patients with Hyperlipoproteinemia(a) and established cardiovascular disease. The study consists of 3 periods: screening, treatment period, and follow-up. Subjects will have 21 visits over a 6 to 12 month period. Procedures include blood draws, genetic testing, diet counseling, SC drug administration, blood collection, ECG, QoL, and physical.

You may be eligible for this study if you meet the following criteria:

• Conditions: TBD, tbd, tbd
• Age: 99 years or below
• Gender: All